Karyopharm Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
85 Wells Ave Ste 210, Newton, Massachuse...Phone Number
(617) 658-0600Website
www.karyopharm.comRevenue
$151.1 MillionStock Symbol
KPTIIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Karyopharm Therapeutics
Karyopharm Therapeutics, headquartered in Newton, Massachusetts, and established in 2008, is a commercial-stage pharmaceutical company specializing in drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases.Explore more
Karyopharm Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Karyopharm Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Karyopharm Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Karyopharm Therapeutics launches new products
Funding: Get notified immidiatlly once Karyopharm Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Karyopharm Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Karyopharm Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Karyopharm Therapeutics
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Karyopharm Therapeutics recently announced quarterly report
Check if Karyopharm Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Karyopharm Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Karyopharm Therapeutics
Compare insights from companies similar to Karyopharm Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Karyopharm Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Karyopharm Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Karyopharm Therapeutics.
Karyopharm Therapeutics financials insights
Gather financial insights about Karyopharm Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$112.5M
2015
Stock Offering
$99M
2017
Stock Offering
$40M
2018
Stock Offering
$155M
Debt
$172.5M
2020
Stock Offering
$172.5M
2025
Other Financing Round
$100M
2026
Stock/Share Issuance
$30M
Karyopharm Therapeutics Tech Stack
A closer look at the technologies used by Karyopharm Therapeutics
Most Recent Scoops
Open Position
Open Position
Project
reported an overall survival hazard ratio of 0.43 (nominal P value of 0.0222) in the SENTRY trial, based on 23 total events across both arms at approximately 12 months median follow-up, with Kaplan-Meier curves separating as early as month nine and continuing to diverge through follow-up.
Medical Research
Project
reported that variant allele frequency (VAF) reduction of greater than 20% was observed at multiple time points in the SENTRY trial, reaching as high as 32% in the combination arm at week 24 versus ruxolitinib alone, consistent with SVR35 and overall survival outcomes and supporting a disease-modifying mechanism via XPO1 inhibition.
Project
Karyopharm Therapeutics News & Media
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will participate in a virtual fireside chat hosted by Cantor on June 8, 2026 at 12:00 p.m. ET. The...Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Achievement of SVR35 with Selinexor plus Ruxolitinib May Predict Overall Survival – – Selected by EHA's Scientific Program Committee as One of the Top Abstracts to be Presented – NEWTON, Mass....Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 1,200 restricted stock units (RSUs) to one newly-hired employee. This RSU award...Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial – – Conference Call Scheduled for Tuesday, June 2, 2026 at 2:00 p.m. ET – NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Karyopharm Therapeutics
Sign Up For FreeTo access detailed company insights
Karyopharm Therapeutics, headquartered in Newton, Massachusetts, and established in 2008, is a commercial-stage pharmaceutical company specializing in drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases.... Read More
